PULMOKINE
Pulmokine is a privately held biopharmaceutical company. Our focus is on pulmonary disease and kinase inhibitor technology, hence our name Pulmokine. The mission of Pulmokine is to develop new therapies for hard-to-treat lung conditions like pulmonary arterial hypertension (PAH) and related disorders. These include pulmonary arterial fibrosis/interstitial lung disease, sarcoidosis and lung cancer.
PULMOKINE
Industry:
Biopharma Biotechnology Health Care
Founded:
2007-01-01
Address:
Rensselaer, New York, United States
Country:
United States
Website Url:
http://www.pulmokine.net
Total Employee:
51+
Status:
Active
Contact:
(518) 472-0952
Email Addresses:
[email protected]
Total Funding:
1000 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API WordPress Wordpress Plugins Google Maps PHP OpenResty LayerSlider Responsive
Current Employees Featured
Founder
Investors List
Broadview Ventures
Broadview Ventures investment in Debt Financing - Pulmokine
Official Site Inspections
http://www.pulmokine.net Semrush global rank: 5.93 M Semrush visits lastest month: 1.39 K
- Host name: a16e665f42988324c.awsglobalaccelerator.com
- IP address: 76.223.105.230
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Pulmokine"
XOMA Royalty Acquires Pulmokine for $20 Million Adding the …
6 days ago In addition, XOMA Royalty will pay success-based consideration contingent on future development and commercial events to Pulmokine stockholders. XOMA Royalty’s net royalties …See details»
Pulmokine - Crunchbase Company Profile & Funding
Organization. Pulmokine . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone Number …See details»
XOMA Royalty Acquires Pulmokine for $20 Million Adding the …
6 days ago In addition, XOMA Royalty will pay success-based consideration contingent on future development and commercial events to Pulmokine stockholders. XOMA Royalty’s net royalties …See details»
Xoma Royalty acquires Pulmokine for $20M - Nasdaq
6 days ago In 2017, Pulmokine licensed seralutinib to Gossamer Bio, Inc., and in 2024, Gossamer Bio signed a global collaboration and license agreement with Chiesi Farmaceutici …See details»
XOMA Royalty Acquires Pulmokine for $20 Million ... - Markets …
6 days ago In addition, XOMA Royalty will pay success-based consideration contingent on future development and commercial events to Pulmokine stockholders. XOMA Royalty’s net royalties …See details»
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royal
XOMA Royalty has the potential to net up to $25 million in milestone payments and earn a low to mid-single digit royalty EMERYVILLE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- XOMA …See details»
Pulmokine Company Profile 2024: Valuation, Investors …
Pulmokine General Information Description. Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders. The company's pulmonary disease and kinase inhibitor technology …See details»
Pulmokine's Leadership Team Team - Team members and org …
Pulmokine's Leadership Team includes Ron Wolff and 2 others. Team members. Larry Zisman. Founder & CEO. Ron Wolff. VP, Affairs & Toxicology. Shreefal Mehta. Co-Founder & …See details»
Pulmokine, Inc. Company Profile | Casper, WY - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Pulmokine, Inc. of Casper, WY. Get the latest business insights from Dun & Bradstreet.See details»
Pulmokine, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Pulmokine, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, and 2 literature, Drug:PK-188, PK-10453. ... pulmokine.net. Private Company | 2007 | …See details»
Pulmokine - Products, Competitors, Financials, Employees, …
About Pulmokine. Pulmokine is a privately held biopharmaceutical company. The mission of Pulmokine is to develop new treatments for pulmonary hypertension and related disorders. …See details»
Choate Represents Pulmokine in its Acquisition by XOMA Royalty
4 days ago Pulmokine is the owner of seralutnib, a Phase 3 asset being studied for its uses in pulmonary arterial hypertension. Seralutinib is being developed and co-commercialized by …See details»
XOMA Royalty Owns Economic Interest In Seralutinib With …
6 days ago XOMA Royalty Chief Investment Officer Brad Sitko said, "We acquired Pulmokine to add seralutinib, a Phase 3 asset with strong mechanistic rationale in PAH, to our growing …See details»
Pulmokine Inc. | Rensselaer, NY, US Startup - gust.com
Pulmokine is developing a novel inhaled PDGF receptor small molecule kinase inhibitor to treat Pulmonary Arterial Hypertension (PAH). PAH is an orphan disease with high mortality. We …See details»
XOMA Royalty Owns Economic Interest In Seralutinib With …
6 days ago XOMA Royalty Corp. (), a biotechnology royalty aggregator, Monday announced that it now owns royalty and milestone interest in seralutinib, a Phase 3 drug being tested for …See details»
Pulmokine Company Profile - Office Locations, Competitors ... - Craft
Pulmokine is a company specializing in the treatments for lung disease. It uses a PDGFR kinase inhibitor technology to develop drugs for the cell proliferation decrease. The company aims to …See details»
XOMA Royalty Acquires Pulmokine for $20 Million Adding the …
6 days ago XOMA Royalty has the potential to net up to $25 million in milestone payments and earn a low to mid-single digit royalty EMERYVILLE, Calif., Dec. 02, 2024 (GLOBE …See details»
XOMA Royalty Acquires Pulmokine for $20M, Adds Phase 3 PAH …
6 days ago XOMA Royalty has acquired Pulmokine for $20 million, gaining rights to seralutinib, a Phase 3 asset being developed for pulmonary arterial hypertension (PAH).The acquisition …See details»
XOMA Royalty Acquires Pulmokine for $20 Million Adding the …
6 days ago In 2017, Pulmokine licensed seralutinib to Gossamer Bio, Inc., and in 2024, Gossamer Bio signed a global collaboration and license agreement with Chiesi Farmaceutici …See details»
Pulmokine - Broadview Ventures
Pulmokine is a biopharmaceutical company developing a novel class of kinase inhibitors for pulmonary related diseases.Its first program, currently in clinical development, is an inhaled …See details»